Pfiz­er lays out am­bi­tious vi­sion for can­cer port­fo­lio in bid to rein­vig­o­rate its busi­ness

Pfiz­er hopes that its cur­rent pipeline could de­liv­er at least eight can­cer block­buster drugs by 2030 as part of its strat­e­gy to dou­ble down on its on­col­o­gy busi­ness af­ter the Seagen ac­qui­si­tion.

In De­cem­ber, the phar­ma gi­ant closed the $43 bil­lion ac­qui­si­tion of the an­ti­body-drug con­ju­gate de­vel­op­er and has since merged Seagen with its es­tab­lished on­col­o­gy di­vi­sion. At its can­cer in­no­va­tion day on Thurs­day, CEO Al­bert Bourla said the new­ly-struc­tured or­ga­ni­za­tion “unites the best from Pfiz­er and Seagen to be­come some­thing greater.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER